Biosimulation Market to Register Substantial Expansion in Coming Years
The biosimulation market is expected to reach USD 2.88 Billion by 2022 from USD 1.20 Billion in 2016 growing at a CAGR of 15.9%
(businesspress24) - The biosimulation market is expected to reach USD 2.88 billion by 2022 from USD 1.38 billion in 2017, growing at a CAGR of 15.9%. Factors such as the increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery and development costs, and growth in the biologics and biosimilars markets are driving the growth of this market.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=838
Based on product & service, the market is segmented into software and services. The biosimulation services segment is expected register the highest CAGR during the forecast period. The high growth in this segment is attributed to the recurring need for services such as data analysis and consulting services.
Based on applications, the biosimulation market is segmented into drug discovery, drug development, and other applications (nutraceuticals and agri-food production). The other applications segment is expected to register the highest CAGR during the forecast period. The increasing use of biosimulation software and techniques by the defense, industrial bioprocessing, nutraceuticals, and agri-food production industries will drive the growth of this market segment in the coming years.
Based on delivery model, the biosimulation market is segmented into ownership models and subscription models. The ownership models segment is expected to register the highest CAGR during the forecast period. Buyers mainly opt for these delivery models due to the security benefits associated with them are the major factors that are expected to drive the growth of the ownership models segment.
Based on the end user, the biosimulation market is segmented into research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (consulting firms, defense research and development organizations, nutraceutical companies, and food and agricultural companies). The pharmaceutical and biotechnology companies are expected to dominate the market during the forecast period. The growth of this segment is mainly attributed to factors such as the increased R&D budgets of pharmaceutical and biotechnology companies and increasing adoption of inorganic growth strategies by different biosimulation service providers.
Among the four regional segments covered in the biosimulation marketdriving the demand for biosimulation in the European region.
Read more: https://www.prnewswire.com/news-releases/biosimulation-market-worth-288-billion-usd-by-2022-667859333.html
Themen in dieser Pressemitteilung:
biosimulation-market-2019
biosimulation-market-latest-trends
biosimulation-market-business
biosimulation-market-growth
biosimulation-market-size
biosimulation-market-share
Unternehmensinformation / Kurzprofil:
Market Research
Datum: 14.08.2019 - 06:53 Uhr
Sprache: Deutsch
News-ID 1538034
Anzahl Zeichen: 5036
Kontakt-Informationen:
Ansprechpartner: Dheeraj Shaha
Stadt:
Northbrook
Telefon: 18886006441
Kategorie:
Biotechnologie
Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 14.08.2019
Anmerkungen:
Diese Pressemitteilung wurde bisher 139 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biosimulation Market to Register Substantial Expansion in Coming Years
"
steht unter der journalistisch-redaktionellen Verantwortung von
MnM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
